蒙特罗莎治疗

US · GLUE #3350 按市值排名上市于 2021

9.74 -0.38 -3.75%

实时 - 追踪5344个代码 - 心跳于202秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了4家。
机构持股总比例下降了2.6个百分点。

机构持股

机构持股比例: 115.91% -2.56pp
机构数量: 228 -4
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund48.02%

Hedge Fund39.67%

VC/PE Fund23.89%

Public Company2.64%

Private Company0.84%

Individual/Insider0.53%

Family Office/Trust0.37%

Government Pension Fund0.28%

Insurance Company0.18%

主要股东截至 2026-06-30

T. Rowe Price Group, Inc. 10.39% · 8.86M 股

BlackRock 8.02% · 6.84M 股

New Enterprise Associates, Inc. 7.84% · 6.69M 股

Dimension Capital Partners, LLC 6.64% · 5.66M 股

TCG Crossover Management, LLC 5.42% · 4.62M 股

Vestal Point Capital, LP 5.39% · 4.60M 股

BVF Partners L.P. 5.23% · 4.46M 股

Baker Bros. Advisors LP 5.09% · 4.35M 股

Vanguard Capital Management, LLC 4.59% · 3.92M 股

State Street Global Advisors 4.37% · 3.73M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 12次买入 · 35次卖出

姓名	职务	持股比例
Markus Warmuth	Chief Executive Officer	0.47%
Edmund Dunn	Vice President & Corporate Controller	0.03%
Matthew Bowen	Corporate Controller & Principal Accounting Officer	0.02%
Sharon Townson	Chief Technology Officer	0.01%
Jennifer Champoux	Chief People & Operations Officer	0.01%
Filip Janku	Chief Medical Officer	0.00%
New Enterprise Associates, Inc.	--	--
Versant Venture Management, LLC	--	--
Christine Siu	Independent Director	--
Andrew Schiff	Independent Chairperson	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-07-15	Markus Warmuth	Chief Executive Officer	Open Market Disposition	-9,500	$23.18
2026-07-14	Jennifer Champoux	Chief People & Operations Officer	Derivative Exercise and Sale	-4,351	$3.98–23.38
2026-07-05	Sharon Townson	Chief Technology Officer	Derivative Exercise and Sale	-6,000	$6.14–24.13
2026-06-30	New Enterprise Associates, Inc.	--	Other Acquisition	+15,000	--
2026-06-30	New Enterprise Associates, Inc.	--	Other Disposition	-1,015,000	--
2026-06-29	Filip Janku	Chief Medical Officer	Derivative Exercise and Sale	-5,407	$13.41–24.50
2026-06-28	Anthony Manning	Director	Derivative Exercise and Sale	-10,000	$4.16–23.11
2026-06-28	Filip Janku	Chief Medical Officer	Derivative Exercise and Sale	-6,000	$7.56–22.95
2026-06-23	Filip Janku	Chief Medical Officer	Derivative Exercise and Sale	-36,000	$7.56–21.42
2026-06-23	Filip Janku	Chief Medical Officer	Intent to Sell (Form 144)	-30,000	$20.71
2026-06-22	Filip Janku	Chief Medical Officer	Automatic Disposition	-5,845	$20.22
2026-06-22	Sharon Townson	Chief Technology Officer	Derivative Exercise and Sale	-3,000	$6.14–20.00
2026-06-22	Jennifer Champoux	Chief People & Operations Officer	Derivative Exercise and Sale	-2,175	$3.98–20.00
2026-06-16	Sharon Townson	Chief Technology Officer	Derivative Exercise and Sale	-3,000	$6.14–19.00
2026-06-16	Jennifer Champoux	Chief People & Operations Officer	Derivative Exercise and Sale	-2,176	$3.98–19.00
2026-06-10	Christine Siu	Independent Director	Other Derivative Acquisition	+25,800	$17.10
2026-06-10	Andrew Schiff	Independent Chairperson	Other Derivative Acquisition	+25,800	$17.10
2026-06-10	Anthony Manning	Director	Other Derivative Acquisition	+25,800	$17.10
2026-06-10	Jan Skvarka	Independent Director	Other Derivative Acquisition	+25,800	$17.10
2026-06-10	Kimberly Blackwell	Independent Director & Member of Scientific Advisory Board	Other Derivative Acquisition	+25,800	$17.10

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:24 · 仅供参考，不构成投资建议，也未考虑您的具体情况。